Welcome to our dedicated page for EBR SYS SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for EBR Systems, Inc. (EBRCZ) provides access to the company’s regulatory reports, including Form 8-K disclosures. In the available Form 8-K, EBR Systems, Inc. is identified as an emerging growth company and reports under Item 2.02 – Results of Operations and Financial Condition.
According to that filing, the company issued a press release describing its commercial and clinical progress and presenting preliminary financial results for a completed quarter and fiscal year. The Form 8-K explains that these figures are unaudited estimates and remain subject to change as the company completes its financial statement closing procedures and the audit of its consolidated financial statements.
The filing also clarifies that the information in Item 2.02 and the related exhibit is furnished, not filed, for purposes of Section 18 of the Exchange Act, and is not automatically incorporated by reference into other registration statements or reports unless specifically stated. This distinction is important for readers who rely on SEC documents to understand the legal status of particular disclosures.
On this page, Stock Titan pairs such filings with AI-powered summaries that explain the structure and key points of documents like Form 8-K. Users can review how EBR Systems, Inc. presents its results of operations, financial condition, and progress updates, while the AI tools highlight important sections and terminology. Real-time updates from the EDGAR system help ensure that new filings, including additional 8-Ks, 10-Ks, or 10-Qs when they appear, are quickly reflected and summarized for easier analysis.
EBR Systems, Inc. is calling a virtual special meeting of stockholders to approve several corporate actions, led by a reverse stock split of its common stock. The Board is seeking authority to implement a reverse split at any whole-number ratio between 1‑for‑5 and 1‑for‑20, at its discretion, while keeping total authorized common shares at 600,000,000. This would sharply reduce the 450,259,169 shares of common stock currently outstanding and increase the pool of authorized but unissued shares, supporting potential future equity or debt financings. CHESS Depositary Interests (CDIs) will not be consolidated; instead, the CDI‑to‑share ratio will change to match the chosen split ratio, with no expected change in the underlying value per CDI.
Stockholders are also being asked to ratify the prior issuance of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement that helped raise approximately A$75.9 million to fund commercialization of the WiSE® CRT system, manufacturing scale‑up, sales expansion, R&D, and working capital. Approval would restore capacity under ASX Listing Rule 7.1 for additional future issuances. A third proposal would allow adjournment of the meeting, if needed, to solicit more proxies. The Board unanimously recommends voting “FOR” all three proposals.
EBR Systems, Inc. is asking stockholders at a virtual special meeting to approve a reverse stock split, ratify prior securities issuances, and allow a potential adjournment to gather more votes. The reverse split would combine between 5 and 20 existing shares into 1 new share, with the exact ratio set later by the Board, and would not reduce the 600,000,000 authorized common shares. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share ratio will change so each CDI continues to reflect the same underlying value after the split.
Because the split reduces shares outstanding without changing authorized shares, the number of authorized but unissued shares would rise, giving the company more flexibility to issue equity in future financings. Stockholders are also asked to ratify the prior issue of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement so those securities are excluded from the 15% ASX Listing Rule 7.1 limit. As of the record date, 450,259,169 common shares (including CDIs) were outstanding and entitled to vote.
EBR Systems, Inc. filed a current report to share that it has issued a press release describing its commercial and clinical progress and preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company noted that the press release, dated January 12, 2026, includes early estimates only, which are unaudited and may change once normal closing and audit procedures are completed.
The press release, titled “EBR Announces Strong Q4 FY 2025 Commercial and Clinical Progress,” is furnished as an exhibit and is not deemed filed for liability purposes under securities laws, nor automatically incorporated into other securities filings unless specifically referenced.
EBR Systems, Inc. reported Q3 2025 results as it begins commercial rollout of its WiSE CRT System following FDA approval on April 11, 2025. Revenue reached $512,093, generating gross profit of $223,722. Operating expenses were $12.1 million (R&D $6.24 million; SG&A $5.86 million), resulting in an operating loss of $11.88 million and a net loss of $12.19 million for the quarter. For the nine months, revenue was $681,797 with a net loss of $34.71 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $70.40 million, including cash and equivalents of $12.64 million and short-term marketable securities of $55.72 million. Notes payable, net, were $40.73 million with maturity in 2027. Inventory increased to $11.17 million as production scaled. Stockholders’ equity was $38.65 million. Shares outstanding were 449,889,450 as of September 30, 2025; the company reported 449,994,658 outstanding as of November 12, 2025.